Exercise and brain health in patients with coronary artery disease: study protocol for the HEART-BRAIN randomized controlled trial

Angel Toval^{*1}, Patricio Solis-Urra^{1,2}, Esmée A Bakker^{1,3}, Lucía Sánchez-Aranda¹, Javier 3 Fernández-Ortega¹, Carlos Prieto¹, Rosa María Alonso-Cuenca^{1,4}, Alberto González-García⁵, 4 Isabel Martín-Fuentes¹, Beatriz Fernandez-Gamez¹, Marcos Olvera-Rojas¹, Andrea Coca-5 6 Pulido¹, Darío Bellón¹, Alessandro Sclafani¹, Javier Sanchez-Martinez¹, Ricardo Rivera-López⁶, Norberto Herrera-Gómez^{1,4}, Rafael Peñafiel-Burkhardt⁶, Víctor López-Espinosa⁶, Sara Corpas-7 Pérez⁴, María Belén García-Ortega⁶, Alejandro Vega-Cordoba⁶, Emilio J. Barranco-Moreno¹, 8 Francisco J. Morales-Navarro¹, Raúl Nieves¹, Alfredo Caro-Rus¹, Francisco J. Amaro-9 Gahete^{7,8,11}, Jose Mora-Gonzalez¹, Sol Vidal-Almela¹, Anna Carlén^{1,9}, Jairo H. Migueles¹, Kirk 10 I. Erickson¹⁰, Eduardo Moreno-Escobar^{4,11}, Rocío García-Orta^{6,11}, Irene Esteban-Cornejo^{1,8,11}, 11 Francisco B. Ortega* 1,11,12 12

- ¹ Department of Physical and Sports Education, Sport and Health University Research Institute (iMUDS), Faculty of Sport
 Sciences, University of Granada, Spain.
- ² Faculty of Education and Social Sciences, University Andres Bello, Viña del Mar, Chile.
- ³ Department of Primary and Community Care, Radboud university medical center, Nijmegen, the Netherlands
- ⁴ Cardiology Service, San Cecilio Clinical University Hospital, Granada, Spain
- 18 ⁵ Department of Nursing, Faculty of Health Sciences, University of Granada, Spain
- ⁶ Cardiology Service, Virgen de Las Nieves University Hospital, Granada, Spain
- 20 ⁷ Department of Physiology, Faculty of Medicine, University of Granada, Granada, Spain
- 21 ⁸ CIBER de Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Granada, Spain.
- ⁹ Department of Clinical Physiology in Linköping, and Department of Health, Medicine and Caring Sciences, Linköping
 University, Linköping, Sweden
- 24 ¹⁰ AdventHealth Research Institute, Neuroscience, Orlando, USA
- 25 ¹¹ Instituto de Investigación Biosanitaria ibs.GRANADA, Granada, Spain
- 26 ¹² Faculty of Sport and Health Sciences, University of Jyväskylä, Jyväskylä, Finland.

27 *** Correspondence:**

- 28 Corresponding authors: Francisco B. Ortega and Angel Toval. Department of Physical Education and
- 29 Sports, Faculty of Sports Science, University of Granada; Carretera de Alfacar, 21. Granada 18071,
- 30 Spain; +(34) 958 24 66 51, fax: +(34) 958 24 94 28; email: ortegaf@ugr.es and
- 31 j.angel.toval@gmail.com
- 32 Trial Sponsor: University of Granada; Crtra. Alfacar, 21. Granada 18071, Spain; +(34) 958 24 66 51
- 33 **Keywords:** ischemic disease, coronary heart disease, cerebral blood flow, cognition, executive
- 34 function, fitness, HIIT, resistance training
- 35 Trial registration: ClinicalTrials.gov: NCT06214624
- 36

38 ABSTRACT

Introduction: Patients with coronary artery disease (CAD), also called coronary heart disease, have a higher risk of developing cognitive impairment and mental health disorders compared to the general population. There is a need to identify effective and sustainable strategies to improve brain health in individuals with CAD, in which physical exercise could play a major role. The overall goal of the HEART-BRAIN randomized controlled trial (RCT) is to investigate the effects of exercise, including different types, on brain health outcomes in patients with CAD, and the underlying mechanisms.
Methods: This three-arm, single-blinded RCT will include 90 adults with CAD, aged 50-75 years. The

46 participants will be randomized into: 1) control group - usual care (n=30), including periodic medical 47 visits and medication management, 2) aerobic high-intensity interval training (HIIT) (n=30), or 3) 48 aerobic HIIT combined with resistance exercise training (n=30). The intervention will last 12 weeks, 49 offering 3 sessions (45min each) per week to the exercise groups, and the study outcomes will be 50 assessed at baseline and after the intervention. The primary outcome of the study is to determine 51 changes in global and regional cerebral blood flow assessed by magnetic resonance imaging. 52 Secondary outcomes include changes in brain vascularization, cognitive measures (i.e., general 53 cognition, executive function and episodic memory), and cardiorespiratory fitness. Additional health-54 related outcomes will be evaluated, and several potential mediators and moderators will be investigated 55 (i.e., brain structure and function, cardiovascular and brain-based biomarkers, hemodynamics, physical 56 function, body composition, mental health, and lifestyle behavior).

57 **Conclusions:** The HEART-BRAIN RCT will provide novel insights on how exercise can impact brain 58 health in patients with CAD and the potential mechanisms explaining the heart-brain connection, such 59 as changes in cerebral blood flow. The results might have important clinical implications by increasing 50 the evidence on the effectiveness of exercise-based preventive strategies that could delay cognitive

- 61 decline in this high-risk CAD population. Our findings will be relevant for patients with CAD,
- 62 researchers and healthcare providers involved in CAD-related clinical care.

63 1 INTRODUCTION

64 More than 300 million people globally are currently living with coronary artery disease (CAD), also 65 called coronary heart disease, (1), which consists of a narrowing or blockage of the coronary arteries 66 mainly caused by atherosclerosis. CAD is the most prevalent cardiovascular disease and a leading 67 cause of mortality and morbidity worldwide (1-5). CAD incurs a significant economic burden, with annual costs estimated at €77 billion in the EU and \$239.9 billion in the USA (3, 6). Recent studies 68 69 have shown that individuals with CAD are at high risk of accelerated decline in cognitive and mental 70 health compared to aged-matched adults without CAD, supporting a nexus between the heart and the 71 brain (7-11). Indeed, the cardiovascular risk factors associated with CAD similarly predispose 72 individuals to cerebrovascular disease, in turn affecting their cerebral perfusion. While pharmaceutical 73 therapies have traditionally been the cornerstone of CAD treatment, exercise is an effective non-74 pharmaceutical intervention for improving cardiometabolic health in these patients (12-15). However, 75 the potential effect of exercise on brain health among individuals with CAD, as well as the mechanisms 76 underlying the heart-brain connection, remain unknown.

77 A key physiological mechanism modulating the heart-brain connection might involve the intricate 78 machinery responsible for supplying blood to the brain. Chronic cerebral hypoperfusion, marked by 79 reduced cerebral blood flow (CBF), impedes the brain's access to vital oxygen and nutrients (9, 16-18). 80 Therefore, a disrupted CBF could play an important role by accelerating cognitive decline and 81 increasing the risk of dementia and mental health disorders in patients with CAD. In turn, exercise 82 could serve as a pivotal factor to enhance CBF, offering a promising non-pharmaceutical adjunct 83 therapy. Limited evidence suggests that exercise may increase CBF and induce brain angiogenesis (i.e., 84 growth of new capillaries). However, these findings are mainly derived from observational evidence 85 and animal studies (19, 20). These hypotheses need to be tested in randomized controlled trials (RCTs)

in humans. The most advanced neuroimaging techniques (particularly in magnetic resonance imaging,
MRI) allow non-invasive (no contrast) methods to assess *in vivo* CBF using the Arterial Spin Labelled
sequence (ASL-MRI) and cerebral vascularization using magnetic resonance angiography (MRA) (21).
These state-of-the-art techniques can provide unique and novel information about the connection of
these two possible mechanisms (i.e. changes in CBF and cerebral vascularization) with cognition and
mental health.

92 Physical exercise is strongly recommended in the clinical management of patients with CAD to reduce 93 disease progression and the risk of major cardiovascular events (13, 22). However, the mechanisms by 94 which different types and doses of exercise induce a variety of physiological responses are still not 95 fully understood. For instance, modalities such as high-intensity interval training (HIIT) or its 96 combination with resistance training are understudied. HIIT may offer superior health benefits, such 97 as larger improvements in cardiorespiratory fitness, compared to moderate intensity continuous 98 training (MICT) in patients with CAD (8-11). However, it is unknown if HIIT is also superior for 99 improving brain health outcomes. On the other hand, resistance training and the combination of aerobic 100 and resistance training remain understudied, despite recommendations by the World Health 101 Organization (WHO) (23) and the European and American clinical guidelines for CAD management 102 (12) (14, 24), all advocating for the combination of aerobic and resistance training for optimal health 103 benefits (12, 13). Since one of the most documented benefits of exercise is the improvement in 104 cardiorespiratory fitness (25-27), and this marker has been consistently linked to better brain health 105 outcomes (28, 29), cardiorespiratory fitness might serve as a potential mediator of the beneficial effects 106 of exercise on the HEART-BRAIN outcomes.

Based on the existing research gaps, we have designed the HEART-BRAIN project, an RCT to investigate the effects of exercise training on brain health outcomes in patients with CAD, including

the underlying mechanisms of the heart-brain connection. Herein, we describe the rationale andmethodology of the HEART-BRAIN RCT.

111 **1.1 Study objectives**

The <u>overall objective</u> of the HEART-BRAIN trial is to investigate the effects of exercise on brain
health outcomes in patients with CAD.

The <u>primary objective</u> of the study is to investigate the effects of aerobic HIIT and aerobic HIIT plus resistance training compared to usual care (i.e. no exercise training) on global and regional CBF in individuals with CAD.

117 <u>Secondary objectives</u>: to determine the effects of aerobic HIIT, and aerobic HIIT plus resistance 118 training compared to usual care on (i) cerebral vascularization, (ii) executive function and general 119 cognition, and (iii) cardiorespiratory fitness. Additionally, we will investigate the role of potential 120 moderators and mediators (see details in statistical analysis section) on the expected effects.

121 <u>Tertiary objectives</u>: to determine the effects of aerobic HIIT, and aerobic HIIT plus resistance training, 122 compared to usual care on additional outcomes related to cardiovascular and brain health, such as brain 123 structure and function, inflammatory, cardiovascular and brain-based biomarkers, cardiac, vascular and 124 transcranial non-invasive hemodynamics, physical function, body composition, mental health and 125 lifestyle behavior.

Our <u>primary hypothesis</u> is that both exercise groups will have a greater increase in CBF compared to
the usual care control group, in which HIIT plus resistance training might have a larger effect size than
HIIT only.

130 2 METHODS AND ANALYSIS

131 **2.1 Design and ethics**

132 The HEART-BRAIN trial is a single-centered, three-armed, single-blinded RCT, in which 90 adults 133 with CAD, between 50-75 years old, living in Granada (Spain), will be enrolled (Figure 1). Participants 134 meeting the eligibility criteria will be randomized into three groups: 1) aerobic HIIT exercise program 135 (n=30), 2) aerobic HIIT plus resistance training exercise program (n=30), and 3) control group - usual 136 care (n=30). The group receiving usual care will be treated as standard care in Spain which includes 137 periodic medical revisions and medication control. The two exercise groups will undertake a 12-week 138 supervised exercise program. All the study outcomes will be assessed at baseline and during the 12-139 week follow-up. Lifestyle behaviors will also be evaluated at mid-point (6 weeks).

140 Eligible participants will receive written information about the study objectives and design, and will 141 provide informed consent before participation. The trial protocol is in accordance with the principles 142 of the Declaration of Helsinki and was approved by the Research Ethics Board of the Andalusian 143 Health Service (CEIM/CEI Provincial de Granada; #1776-N-21 on December 21st, 2021). The RCT is 144 registered on Clinicaltrials.gov (NCT06214624; submission date: December 22nd, 2023) and the study 145 protocol and statistical analysis plan were uploaded before the last participants were randomized (submission date: January 29th, 2024). The study has been designed following the Standard Protocol 146 147 Items for Randomized Interventional Trials (SPIRIT) (30, 31) and the SPIRIT-Outcomes 2022 148 Extension (32) (Supplementary Table 1). Any significant changes to the protocol will be reported to 149 the trial registry and the Research Ethics Board, which is in line with the SPIRIT guidelines. Moreover, 150 participants in the HEART-BRAIN trial are insured under a social responsibility policy from the 151 University of Granada, which covers ancillary services, post-trial care or compensation if necessary. 152 There are no financial rewards provided to participants for their involvement in the study.

153 2.2 Recruitment and screening

154 Participants with CAD will be recruited from two public hospitals in Granada, Spain: the "Hospital 155 Universitario Virgen de las Nieves" and the "Hospital Universitario Clínico San Cecilio". Recruitment 156 started in May 2022, and we plan to enroll a minimum of 90 patients, aged 50-75, with stable CAD 157 (phase III) proven by invasive coronary angiography or CT with at least one coronary stenosis with > 158 50% luminal reduction. A complete list of eligibility criteria is presented in **Table 1.** Eligible patients 159 will be screened by the clinical and research team in three steps (Figure 1): 1) screening by the 160 clinicians of the research team (i.e., based on clinical history); 2) screening based on a phone call 161 conducted by the research team; and 3) screening during the baseline assessments including the 162 cardiopulmonary exercise test (CPET) and echocardiography. Participants will be recruited in waves, 163 with 10 to 20 people in each wave, throughout the year. In accordance with the CONSORT flow 164 diagram (33), we will note the number of patients that were assessed for eligibility by the clinical and 165 research team, the number of excluded patients (indicating reason for exclusion) during the enrollment 166 phase and the number of randomized participants. For the allocation, the number of participants 167 allocated to the intervention groups and the number of participants who received the intervention (with 168 reasons for nonadherence to the allocated arm) will be noted. The number of participants who were 169 lost to follow-up (dropouts) and who discontinued the intervention (including reasons) will be reported. 170 Finally, the number of participants that were included in the analyses using the intention-to-treat and 171 per-protocol databases will be described together with the reasons for the exclusion from the analytic 172 database.

173 2.3 Randomization

174 Randomization will occur on a rolling basis and only after the completion of all baseline assessments,
175 through REDCap Software (34). Participants will be randomized using a 1:1:1 ratio and stratified by

age (<65 years or ≥ 65 years) and sex (female or male). To ensure adequate allocation concealment,
this procedure will be carried out by a blinded external researcher (Dr. Cabanas-Sanchez, Autonomous
University of Madrid, Spain).

179 **2.4 Blinding**

Participants cannot be blinded due to the nature of the interventions, as they will inevitably become aware of their group allocation. Nonetheless, the principal investigator (PI) and the research team members participating in the post-intervention evaluations (who are not involved in monitoring the exercise sessions) will be blinded to the group assignments. Unblinding will only occur in case of an unexpected adverse event involving a participant and will only be done by the PI or a physician.

185 **2.5 Interventions**

A detailed and broader description of the program will be further extended in the Consensus on Exercise Reporting Template (CERT) study protocol of the HEART-BRAIN trial (*manuscript in preparation*). Briefly, participants will be randomized to one of the following three groups:

Aerobic high-intensity interval training (HIIT). 12-week duration, 3 times/week. This consists of a 4x4 HIIT (preferably on the treadmill): 4 intervals of 4 minutes at high intensity (85-95% of HRmax), interspersed with 3 intervals of 3 minutes of active resting at ~70% of HRmax. All sessions include 10 minutes of warm-up and 10 minutes of cool-down, resulting in a total session time of 45 minutes. During the familiarization period (first two weeks), participants will progress from moderate-intensity training to the target HIIT.

Aerobic HIIT plus resistance training. 12-week duration, 3 times/week. The aerobic part consists of a
 3x4 HIIT (preferably on treadmill), with 3 intervals of 4 minutes at high intensity (85-95% of HRmax),

interspersed with 2 intervals of 3 minutes of active resting (~70% of HRmax). The resistance part
consists of 2 rounds of an 8-exercise circuit (a combination of upper and lower body exercises using
elastic bands and body weight) with a ratio of 20 seconds of effort followed by 40 seconds of resting.
Sessions will have 5 minutes of warm-up on the treadmill and 5 minutes of cool-down walking around
the gym, for a total session time of 45 minutes.

202 <u>Control group – usual care</u>. The control group will be treated as usual in outpatient Phase III, which in 203 Spain includes periodic medical revisions where the clinician may provide patients with lifestyle and 204 clinical advice (e.g., inform about exercise limitations, if any, and nutrition recommendations, stress 205 management) and medication control. In addition, in the control group, we will apply the wait-list 206 strategy, offering participants the HIIT supervised program described above, once data collection for 207 pre- and post-intervention assessments is completed.

208 All intervention groups will receive the same usual care. The HIIT program and the HIIT part of the 209 combined HIIT plus resistance training program have been designed based on the guidelines for the 210 delivery and monitoring of HIIT in clinical populations (35) and meet the aerobic recommendations of 211 the WHO guidelines, as it surpasses the minimum of 75 minutes of vigorous intensity or 150 minutes 212 of moderate intensity per week, or a combination of them (23). The combined HIIT plus resistance 213 training program meets the aerobic and resistance components of the WHO recommendations, as it has 214 3 sessions of resistance training per week while WHO guidelines recommend at least 2 sessions 215 involving major muscle groups. Both exercise programs have been designed to provide an estimated 216 isocaloric workload (same energy expenditure) in terms of intensity and duration.

Exercise programs will take place in the Sport and Health University Research Institute (iMUDS) at
the University of Granada. Accredited expert trainers with a BSc degree in sports sciences will lead all

supervised sessions with a ratio of 1:1 (one trainer, one participant). Exceptionally (e.g., scheduling
conflicts), a ratio of 1:2 will be used.

221 Both training programs are individually tailored. Exercise prescription, monitoring, and decisions for 222 progression will be based on the percentage of HRmax and the 10-point Borg Rating of Perceived 223 Exertion scale (RPE) (36). HRmax will be determined during the CPET with electrocardiogram (ECG) 224 and gas exchange analyzer performed at baseline (see section 2.3.2). Furthermore, symptoms and blood 225 pressure will be monitored before, during, and after the exercise sessions. Participants taking beta-226 blocker medications often have a blunted HR response (35), which could also affect the HRmax 227 obtained in the CEPT. Thus, while the HRmax will be used as a reference for exercise intensity, 228 participants will be encouraged to learn and use RPE. This indicator will be used as a reference in case 229 of discordance between HR and RPE targets. In addition, the trainers will use their judgment to adapt 230 the intensity, particularly during the resistance training, because RPE might be less reliable in 231 inexperienced participants (35).

232 **2.6** Adherence, attendance, and compliance

233 Since the term adherence has been used with different meanings in the literature, in our study we will 234 refer to two concepts more unequivocally used: attendance and compliance. Attendance will be defined 235 as the percentage of sessions attended by the participant (recorded by the trainers) divided by the 236 number of exercise sessions offered (12 weeks x 3 sessions/week = 36, yet holidays and logistic reasons 237 may lead to slight deviations among waves and participants). Compliance will be defined as the 238 percentage of sessions in which the specified amount of time (i.e., HIIT 6.5 min and HIIT plus 239 resistance training 4.5 min) is spent within the target HR intensity, divided by the number of exercise 240 sessions with valid data (e.g., sessions with technical issues of the HR bands will be excluded). The 241 familiarization phase (i.e., the first two weeks of the exercise intervention) will not be considered for

the compliance calculation. The amount of time, i.e., HIIT 6.5 min; HIIT plus resistance training 4.5 min, in the target HR intensity is based on the exercise protocol and the guidelines for HIIT prescription and monitoring in clinical populations (35): "for the first high-intensity interval, allow the entire 4minute period to reach the HR target zone, for subsequent high intensity intervals (i.e., 2nd, 3rd, and/or 4th), allow 2-minutes (halfway) to reach the HR target zone".

- All protocol deviations will be recorded and reported (e.g., change in pre-defined inclusion/exclusioncriteria, baseline and post assessments, data cleaning/processing).
- 249 2.7 Safety and adverse events

Although HIIT has been shown to be low risk in patients with CAD (37-39), the safety of our participants is the highest priority in the study. For these purposes, we followed the guidelines for using HIIT in clinical populations and have applied in our study the recommended exclusion criteria (35). Further, CPET together with cardiac and vascular ultrasound will be performed at baseline and serve as a clinical assessment to confirm the absence of underlying conditions that contraindicate exercise.

255 The center where the exercise training sessions will be delivered (iMUDS) is located in the Hospital 256 area next to the emergency unit (200 meters) and the ambulance unit (600 meters). A trained allied 257 health professional (nurse or physician) will be present in the center during the training sessions to 258 guarantee a timely response in case of an adverse event. The center has a fully equipped trolley with a 259 first aid kit and automatic defibrillator and obtained the Andalusian Certification of "Cardioprotected 260 Center" (Decreto 22/2012 of February 14th). Furthermore, all members of the project team will receive 261 certified training courses in cardiopulmonary resuscitation and the use of a semi-automatic 262 defibrillator.

In case of an adverse event, we will follow the protocol recommended by the Spanish Council of 263 264 Cardiopulmonary Resuscitation (CERCP). The number and reasons for adverse events (e.g., falls, 265 injuries, musculoskeletal problems, major cardiovascular events, and any other events potentially 266 related to the implementation of the trial protocol) occurring at any time during the study will be 267 collected, reported, and separately described for each study arm. The participants allocated to the 268 exercise group will be able to communicate any adverse events during their regular contact with the 269 project team (i.e., 3 sessions/week), whereas those allocated to usual care will be asked to report any 270 adverse event promptly, and will be called by phone for these regards at weeks 3, 9 and 12. Adverse 271 events will be described in a table in the main HEART-BRAIN manuscript. Each adverse event will 272 be clinically ascertained to judge whether the event was due to exercise in the corresponding study arm 273 using an adverse event algorithm (i.e., Liverpool Causality Assessment Tool) (40) and recorded 274 according to the Common Terminology Criteria for Adverse Events, (CTCAE) (41) by an experienced 275 cardiologist (EME) after discussion and consensus with the rest of the cardiologists involved in the 276 project.

277 **2.8 Outcomes**

The primary, secondary, and additional outcomes, the assessment instruments, and the data collection time points are summarized in **Table 2**. All outcome-related measures, data processing, and statistical analyses will be performed by staff blinded to the intervention assignment.

281 **2.8.1. Primary Outcome Measures:**

282 <u>Change in cerebral blood flow</u> (timepoint: baseline and 12-weeks): CBF (mL/100 g/min) will be 283 measured using the MRI technique of pseudo-continuous arterial spin labeling (pCASL) (42, 43). We

will analyze both global and regional CBF, as determined by voxel-wise analysis to measure local
perfusion (acquisition parameters in Table 3).

286 **2.8.2 Secondary Outcome Measures:**

287 <u>Change in cerebral vascularization</u> (baseline to 12 weeks): Cerebral vascularization will be measured 288 using the time-of-flight-magnetic resonance angiography (TOF-MRA). This sequence allows imaging 289 flow within vessels revealing the cerebrovascular anatomy without the need to administer contrast. 290 Thus, the analysis of TOF-MRA provides the number, distribution, and morphology of intracranial 291 vessels (acquisition parameters in **Table 3**).

292 Change in cognitive outcomes (baseline to 12 weeks): A comprehensive neuropsychological battery 293 will assess several domains of cognition (Table 4). General cognition will be assessed by the Montreal 294 Cognitive Assessment (MoCA) test (44). Additionally, the battery includes paper-and-pencil tests 295 (Trail making test (45) and Digit Symbol Substitution Test (46)), National Institutes of Health (NIH) 296 Toolbox tests (Dimensional Change Card Sort Test, Flanker Test, Picture Sequence Memory Test, and 297 List Sort Working Memory Test) (47) and a programmed test in E-prime software (Spatial Working 298 Memory Test) (48). Detailed information about the cognitive tests has been previously described (49). 299 The cognitive indicators will be transformed into standardized z-scores by calculating the difference 300 between each individual raw score and the group average score at baseline, and then dividing by the 301 standard deviation at baseline. We will determine the effects of the interventions on the cognitive 302 outcomes (e.g., general cognition, cognitive flexibility, inhibition control, working memory, 303 processing speed and episodic memory). To guarantee reliable evaluations, all paper-and-pencil tests 304 will be independently scored by two trained evaluators, with any discrepancies resolved through mutual 305 agreement.

Change in cardiorespiratory fitness (baseline to 12 weeks). Cardiorespiratory fitness will be assessed 306 307 by a standardized ramp CPET to exhaustion on a treadmill (h/p/cosmos, Nussdorf, Germany), in 308 accordance with the American College of Sports Medicine Guidelines (50). We decided to use a ramp 309 protocol with small increments, and opted for a standardized, instead of individualized, protocol to be 310 able to compare the time-to-exhaustion (test duration, excluding warm-up) between participants as an 311 additional indicator of exercise capacity and cardiorespiratory fitness, in addition to the peak oxygen 312 uptake. CPET will be carried out by trained staff and under the supervision of a physician. The protocol 313 begins with a 3-minute warm-up phase, during which the speed gradually increases to 4.8 km/h. 314 Following this, the slope will be increased by 1% every 30 seconds until exhaustion or any other 315 indication for test cessation (50), followed by a 3-minute recovery phase. This ramp protocol equates 316 the 3-min increment Bruce tests, as indicated in the American College of Sports Medicine Guidelines 317 (50). The respiratory exchange will be monitored with a dilution flow system (Omincal, Maastricht 318 Instruments, Maastricht, the Netherlands), generating output data at 5-second intervals. A 12-lead 319 electrocardiogram (AMEDTEC ECGpro, GmbH, Aue, Germany) will be continuously monitored by a 320 physician during the test. Heart rate will also be registered with a Polar H10 monitor (including chest 321 band and watch). Systolic and diastolic blood pressures will be measured with an automatic 322 sphygmomanometer (Tango M2; SunTech Medical Inc., NC, USA) every 3 minutes during exercise, 323 and after 3 and 5 minutes of recovery. The RPE will be asked every 3 minutes during the test (51). 324 Peak oxygen uptake (Peak VO₂) will be defined as the highest rolling 30-second average during the 325 test. Since the heart rate response might be blunted due to beta-blockers and the oxygen uptake plateau 326 is not always observed, staff will note whether participants reach a respiratory exchange ratio (RER) 327 of 1.1 or higher, as RER is one of the most robust indicators of maximal effort in these patients.

328

330 **2.8.3 Other Outcome Measures:**

331 Brain structure and function

332 CBF (primary outcome), cerebral vascularization (secondary outcome), along with other brain 333 structure and function outcomes will be assessed by MRI at the Mind, Brain and Behavior Research 334 Centre (CIMCYC) at the University of Granada. A Siemens Magnetom PRISMA Fit 3T scanner with 335 a 64-channel head coil will be used. Table 3 shows the imaging sequences that will be performed for 336 each participant in acquisition order. Participants will be asked to wear comfortable clothing, MRI 337 eligibility criteria will be checked (e.g., not having metallic implants or claustrophobia), and 338 participants will provide additional informed consent specifically for MRI scans. When doubts exist 339 about the compatibility of certain implants, an experienced radiologist will check the composition and 340 material of the implant and inform about the compatibility with MRI before the scanning takes place. 341 Standard MRI sequences will be conducted for approximately 60 minutes. A radiologist will review 342 structural sequences to detect any incidental findings. If any of them are discovered, the radiologist 343 will communicate with the participant for further examination. Besides CBF and cerebral 344 vascularization, the following brain MRI outcomes will be examined (acquisition parameters are 345 shown in **Table 3**):

<u>Change in blood-brain barrier (BBB) permeability</u> (baseline and 12 weeks). BBB permeability will be
assessed by a recently developed neuroimaging technique that measures water exchange across the
BBB using 3D diffusion-prepared arterial spin-labelled perfusion MRI (52).

<u>Change in brain morphology</u> (baseline and 12 weeks). MRI will measure brain morphology including
 volume, area, cortical thickness, and shapes by a T1-weighted MPRAGE (Magnetization Prepared
 Rapid Gradient Echo) structural sequence.

352 <u>Change in white matter structure</u> (baseline and 12 weeks). MRI will measure white matter 353 microstructure by a diffusion-weighted acquisition sequence.

354 <u>Change in brain function</u> (baseline and 12 weeks). MRI will measure brain function during resting state
 355 and measures of brain activity and connectivity will be calculated.

356 **Biological samples**

357 The HEART-BRAIN trial aims to examine various biomarkers by the analysis of blood, saliva, and 358 fecal samples. A trained nurse will collect blood samples from participants under fasting conditions 359 (08:00 to 10:00 a.m.) at the Virgen de las Nieves University Hospital. For post-assessments, blood 360 extraction will be done within the first 3-5 days after the last training session. Briefly, three 361 ethylenediaminetetraacetic acid (EDTA) tubes, two citrate tubes, two serum tubes, and one PAXGENE 362 tube will be collected corresponding to a total of approximately 30 ml of blood per participant visit. 363 Part of the blood samples obtained from each participant will be processed directly at the Hospital (1 364 EDTA, 1 citrate, and 1 serum tube), and the remaining samples will be aliquoted and stored at -80°C 365 for later studies. Saliva samples will be collected into sterilized plastic containers and aliquoted into 366 1.5mL Eppendorf. Fecal samples will also be collected under standardized conditions using sterile 367 plastic containers and stored at -80°C. Table 5 outlines the specifications of the samples, initial 368 analyses, and preliminary analysis plans. Nevertheless, samples will be analyzed using the best 369 available methods at the time of processing. Blood analyses will cover conventional biochemical 370 measurements, cardiovascular, brain-peripheral, and inflammatory biomarkers, telomere length, and 371 genetic analysis. Saliva and fecal samples will undergo metagenomic analysis to study the microbiome. 372 Some of the analyses will be conducted as additional funding is obtained. Briefly, the main outcomes 373 planned from biological samples include:

374	Change in cardiovascular biomarkers (baseline and 12 weeks). Blood samples will be used to determine
375	concentrations of cardiovascular biomarkers including glucose, insulin, triglycerides, high-density
376	lipoprotein (HDL), low-density lipoprotein (LDL), and total cholesterol.
377	Change in brain-peripheral biomarkers (baseline and 12 weeks). Blood and saliva samples will be used
378	to determine the concentration of peripheral brain biomarkers such as brain-derived neurotrophic factor
379	(BDNF), vascular endothelial growth factor (VEGF), insulin-like growth factor 1 (IGF-1), cathepsin
380	B (CTSB), amyloid and tau protein levels, as well as novel neurodegenerative biomarkers based on
381	new evidence available at the time of the analysis.
382	Change in inflammatory biomarkers (baseline and 12 weeks). Blood samples will be used to determine
383	concentrations of inflammatory peripheral biomarkers such as tumor necrosis factor-alpha (TNF-
384	alpha), interleukins, and both traditional and high-sensitivity C-reactive proteins.
385	Change in gene expression and epigenetics (baseline and 12 weeks). Blood samples will be stored for
386	epigenetic and gene expression changes.
207	
387	<u>Change in oral and gut microbiota</u> (baseline and 12 weeks). Saliva and fecal samples will be used to
388	determine oral and gut microbiota including the most representative phyla (i.e., firmicutes,
389	Bacteroidetes, and proteobacteria).
390	Hemodynamics
570	Temouy namies
391	Hemodynamic changes (baseline and 12 weeks). Non-invasive hemodynamic parameters will be
392	measured using ultrasound (Vivid E95, GE Healthcare) at three levels: 1) vascular (main carotid artery
393	and vertebral artery, with measurements of intima-media thickness, flow, and wall strain, as well as
394	registration of presence of atherosclerotic plaques) 2) cardiac (i.e., cardiac dimensions and volumes
	registration of presence of aneroselerotic plaques), 2) carefue (ne., carefue antensions and volumes,

575	systolic and diastolic function such as ejection fraction, strain deformation, and myocardial work), and
396	3) transcranial (i.e., systolic and diastolic flow velocity in the middle cerebral artery). Image acquisition
397	and analysis will be carried out by cardiologists with expertise in ultrasonography.
200	
398	<u>Change in blood pressure</u> (baseline and 12 weeks). Resting systolic and diastolic blood pressure will
399	be assessed by a validated automated blood pressure monitor (Omron M3, Intellisense, OMRON
400	Healthcare Europe, Spain) in the sitting position after 5 minutes of rest and with the left arm resting on
401	a table at heart level. Three readings will be collected with 2-minute intervals in between. Blood
402	pressure will be calculated as the average of the last two blood pressure readings (53).
403	<u>Change in arterial stiffness</u> (baseline and 12 weeks). Arterial stiffness will be assessed using the pulse
404	wave analysis and carotid-femoral pulse wave velocity (aortic-PWV) by applanation tonometry
405	determined by the SphygmoCor® XCEL PWA/PWV (AtCor Medical, Sydney, Australia).
10.6	
406	Physical functioning and body composition
407	Additional physical function and body composition outcomes will include:
407	Additional physical function and body composition outcomes will include:
407 408	Additional physical function and body composition outcomes will include: <u>Change in physical function</u> and fitness (baseline and 12 weeks). The Senior Fitness Test, including
407 408 409	Additional physical function and body composition outcomes will include: <u>Change in physical function</u> and fitness (baseline and 12 weeks). The Senior Fitness Test, including the 6-min walking test) will be used to assess overall physical functioning. Senior Fitness Test battery
407 408 409 410	Additional physical function and body composition outcomes will include: <u>Change in physical function</u> and fitness (baseline and 12 weeks). The Senior Fitness Test, including the 6-min walking test) will be used to assess overall physical functioning. Senior Fitness Test battery assesses upper and lower body strength, aerobic capacity, walking speed, balance, and flexibility (54).
407 408 409 410 411	Additional physical function and body composition outcomes will include: <u>Change in physical function</u> and fitness (baseline and 12 weeks). The Senior Fitness Test, including the 6-min walking test) will be used to assess overall physical functioning. Senior Fitness Test battery assesses upper and lower body strength, aerobic capacity, walking speed, balance, and flexibility (54). Perceived physical fitness (cardiorespiratory fitness, muscular strength, speed-agility, flexibility and
407 408 409 410 411 412	Additional physical function and body composition outcomes will include: <u>Change in physical function</u> and fitness (baseline and 12 weeks). The Senior Fitness Test, including the 6-min walking test) will be used to assess overall physical functioning. Senior Fitness Test battery assesses upper and lower body strength, aerobic capacity, walking speed, balance, and flexibility (54). Perceived physical fitness (cardiorespiratory fitness, muscular strength, speed-agility, flexibility and overall fitness) will be assessed using the International Fitness Scale (IFIS) (55). In addition, muscular
407 408 409 410 411 412 413	Additional physical function and body composition outcomes will include: <u>Change in physical function</u> and fitness (baseline and 12 weeks). The Senior Fitness Test, including the 6-min walking test) will be used to assess overall physical functioning. Senior Fitness Test battery assesses upper and lower body strength, aerobic capacity, walking speed, balance, and flexibility (54). Perceived physical fitness (cardiorespiratory fitness, muscular strength, speed-agility, flexibility and overall fitness) will be assessed using the International Fitness Scale (IFIS) (55). In addition, muscular strength with be measured with a combination of some of the Senior Fitness Test and handgrip strength
407 408 409 410 411 412 413 414	Additional physical function and body composition outcomes will include: Change in physical function and fitness (baseline and 12 weeks). The Senior Fitness Test, including the 6-min walking test) will be used to assess overall physical functioning. Senior Fitness Test battery assesses upper and lower body strength, aerobic capacity, walking speed, balance, and flexibility (54). Perceived physical fitness (cardiorespiratory fitness, muscular strength, speed-agility, flexibility and overall fitness) will be assessed using the International Fitness Scale (IFIS) (55). In addition, muscular strength with be measured with a combination of some of the Senior Fitness Test and handgrip strength test. In brief, each participant will be encouraged to perform the maximal isometric force twice with
407 408 409 410 411 412 413 414 415	Additional physical function and body composition outcomes will include: <u>Change in physical function</u> and fitness (baseline and 12 weeks). The Senior Fitness Test, including the 6-min walking test) will be used to assess overall physical functioning. Senior Fitness Test battery assesses upper and lower body strength, aerobic capacity, walking speed, balance, and flexibility (54). Perceived physical fitness (cardiorespiratory fitness, muscular strength, speed-agility, flexibility and overall fitness) will be assessed using the International Fitness Scale (IFIS) (55). In addition, muscular strength with be measured with a combination of some of the Senior Fitness Test and handgrip strength test. In brief, each participant will be encouraged to perform the maximal isometric force twice with each hand using a hand dynamometer (TKK 5101 Grip D, Takey, Tokyo Japan). The maximum value
407 408 409 410 411 412 413 414 415 416	Additional physical function and body composition outcomes will include: <u>Change in physical function</u> and fitness (baseline and 12 weeks). The Senior Fitness Test, including the 6-min walking test) will be used to assess overall physical functioning. Senior Fitness Test battery assesses upper and lower body strength, aerobic capacity, walking speed, balance, and flexibility (54). Perceived physical fitness (cardiorespiratory fitness, muscular strength, speed-agility, flexibility and overall fitness) will be assessed using the International Fitness Scale (IFIS) (55). In addition, muscular strength with be measured with a combination of some of the Senior Fitness Test and handgrip strength test. In brief, each participant will be encouraged to perform the maximal isometric force twice with each hand using a hand dynamometer (TKK 5101 Grip D, Takey, Tokyo Japan). The maximum value of each hand will be taken and averaged in kilograms (kg) as an indicator of upper-body muscular

417 strength. Lower body muscular strength will be assessed using the chair stand test (number of 418 repetitions). Upper body muscular strength will be assessed using the arm curl test (number of 419 repetitions). Perceived strength will be assessed using a single item from the IFIS (55).

420 <u>Change in body composition</u> (Baseline and 12 weeks). Body mass index (BMI, kg/m^{^2}) will be 421 computed from height and weight measured with SECA instruments following standardized 422 procedures. Body composition (i.e., lean mass, kg, fat mass, kg, and bone mineral content and density, 423 z-score) will be assessed using a dual-energy x-ray absorptiometer and a TANITA's Bioelectrical 424 Impedance Analysis (TANITA MC-980MA-N plus, Amsterdam, the Netherlands). We will also 425 conduct MRI of the abdominal region to obtain information on overall visceral adipose tissue, specific-426 organ adipose tissue, and subcutaneous abdominal adiposity.

427 Mental health and lifestyle behaviors

428 A battery of questionnaires will be administered to evaluate the following dimensions in relation to429 mental health and lifestyle behavior:

430 Change in depressive symptoms (baseline and 12 weeks) will be assessed using the Global 431 Deterioration Scale (56), and the Hospital Anxiety and Depression Scale (HADS) (57); change in 432 anxiety symptoms (baseline and 12 weeks) will be assessed using the HADS questionnaire (57); change 433 in stress (baseline and 12 weeks) will be assessed using the Perceived Stress Scale (58); change in 434 loneliness (baseline and 12 weeks) will be assessed using the UCLA Loneliness Scale (59); change in 435 self-esteem (baseline and 12 weeks) will be assessed using the Rosenberg Self-Esteem Scale (60); 436 change in social support (baseline and 12 weeks) will be assessed using the Social Provisions Scale 437 (61).

438 <u>Change in health-related quality of life</u> (baseline and 12 weeks) will be assessed using the SF-36 form 439 (62), which provides an 8-scale profile of functional health and well-being scores (i.e., physical 440 functioning; role limitations due to physical problems; bodily pain; general health perceptions; 441 energy/vitality; social functioning; role limitations due to emotional problems; and mental health) as 442 well as psychometrically-based Physical Component Score (PCS) and Mental Component Score 443 (MCS).

444 <u>Change in physical activity and sedentary behaviors</u> (baseline, 6 and 12 weeks). Physical activity and 445 sedentary behavior will be measured using the accelerometer Axivity AX at baseline and 6-weeks. The 446 accelerometer will be attached to the non-dominant wrist for 9 consecutive days, the sampling 447 frequency will be set at 100 Hz, and the accelerometer raw data processing will be conducted using 448 open-source software tools to ensure transparency and replicability of the methods (63). Additionally, 449 participants will complete the short version self-reported International Physical Activity 450 Questionnaire(64) at baseline and 12 weeks.

451 <u>Change in duration and sleep quality</u> (baseline and 6 weeks). Sleep duration (hours/night) will be 452 computed from the accelerometer Axivity AX and diaries, and an open-source software will be used 453 to process the raw data recordings (63). In addition, participants will complete a single-item question 454 on usual sleep duration. Sleep quality (e.g. sleep regularity, sleep efficiency, latency, number and total 455 time of waking up after sleep onset) will also be assessed using the accelerometer Axivity AX.

456 <u>Change in diet behaviors</u> (baseline, 6 and 12 weeks). Diet behaviors will be self-reported using the 14457 item Questionnaire of Mediterranean Diet Adherence (PREDIMED-14) with an additional question for
458 supplement intake.

459 Additional variables related to health, lifestyle and genotype will be measured for descriptive purposes, 460 for covariate adjustment in the analyses when necessary or for interaction with the intervention effects. 461 Examples include biological sex, ethnicity, educational level, smoking habits, alcohol consumption, 462 medication, comorbidities (e.g., dyslipidemia, hypertension, or type 2 diabetes), family history of 463 dementia, handedness, and COVID-19 history. Additionally, genotyping at baseline will be conducted 464 for well-known Single Nucleotide Polymorphisms (SNP) for brain health, such as Apolipoprotein E 465 (APOE) and BDNF genotypes, and additional relevant SNPs based on an updated literature search. 466 The genotyping analysis is conducted to test gene-exercise interaction as we have done in previous 467 RCTs (49).

468 **2.9** Sample size and statistical analysis

A detailed description of the statistical analysis plan, including a sample size calculation, for the
HEART-BRAIN trial has been pre-registered and published on Clinicaltrials.gov (NCT06214624;
submission date: January, 2024).

472 **2.9.1 Sample size**

The HEART-BRAIN project has been designed to detect a low-to-medium size change (i.e. effect size
Cohen d=0.35) with an alpha of 0.05 and beta of 0.2 (power 0.8). The trial has been powered for a 7%
dropout during the intervention (based on our previous RCTs (49)). Thus, the estimated sample size,
for repeated-measures ANOVA using G*Power (version 3.1.9.7), was 90 participants (30 in each study
arm).

478 **2.9.2 Framework and timing**

A superiority hypothesis testing framework will be used. In the main analyses, we will compare whether both exercise interventions (HIIT only or HIIT plus resistance training) are superior to usual care (no exercise training). The final analyses will be performed after collecting and processing the data of the primary and secondary outcomes. The time points for data collection of each outcome are explained in section 2.4.

484 **2.9.3 Statistical interim analyses and stopping guidance**

No pre-specified interim analyses will be performed, and therefore, a stopping guidance is not applicable. Basic analyses (not including the primary outcome) have been performed as required by the final report for the funding agencies, after completion of the first 58 participants. The basic analyses have been performed by a researcher who is not involved in data collection (EAB). The results of the basic analyses have not been discussed with other members of the research team involved in the evaluations or interventions to avoid any bias during the implementation of the study, data collection or processing. These basic analyses have not led to any protocol deviations.

492 **2.9.4** Brief description of the primary and secondary analyses

The main analyses will consist of the intention-to-treat analyses for the primary and secondary outcomes using a constrained baseline (meaning baseline adjusted) linear mixed model, which accounts for baseline differences among the study groups. The model will include fixed effects for time (two levels) and treatment (three levels) as well as the unique participant identifier as a random effect. If the global test of significance indicates between-group differences, pairwise comparisons will be explored. Although no adjustments for multiplicity will be performed, family-wise type 1 error rate on the primary outcome will be retained by using a hierarchical analytic approach. The prespecified

hierarchical hypotheses will be tested using the prespecified sequence: HIIT plus resistance training versus usual care, HIIT versus usual care, and HIIT plus resistance training versus HIIT. No additional adjustments for covariates will be made (except for baseline adjustments of the outcome). The main statistical analyses will be performed by an independent researcher (EAB), who is not involved in the recruitment, evaluations, and interventions, and who will be blinded to treatment allocation by coding the intervention arms (e.g., A, B, C). The same approach will be applied to secondary and tertiary outcomes.

507 2.9.5 Moderation, mediation, and other secondary analyses

Although the RCT is not powered for subgroup analyses, we will perform moderation analyses by exploratory subgroup analyses for age, sex, education level, baseline level of the study outcome (stratified on the median), and APOE genotype. Likewise, we plan to explore potential mechanisms driving effects on outcomes. For example, we will run a formal mediation analysis to test whether changes in cardiorespiratory fitness explain exercise-derived changes in brain and cognitive outcomes, and whether changes in CBF or vascularization mediate exercise-derived changes in cognitive outcomes.

515 **2.9.6 Confidence intervals and P values**

All statistical tests will be two-tailed. P for significance will be set at 0.05 and 95% confidence intervals will be estimated. No adjustments for multiplicity will be made as multiplicity adjustments may be of lesser importance in the case of distinct treatment arms (65). Since only one primary outcome has been defined, other outcomes do not require adjustment for multiple testing. However, we will include a hierarchical analytic approach for the exercise interventions tested and the primary outcome.

521 **2.9.7** Analysis populations

522 We plan to use two approaches for the statistical analyses:

523 1. Intention-to-treat (main analysis): This will be used for our primary analyses and includes all 524 randomized participants. With this approach, all randomized participants are included in the analysis, 525 based on the groups to which they were initially randomly assigned to. This implies that some 526 participants will have valid data at both time points, while some might have missing data at baseline 527 or post-intervention assessment, which is sometimes named as "available-case intention-to-treat".

2. Per-protocol and additional sensitivity analyses: This dataset will be used for our secondary analyses and includes all participants with \geq 70% attendance. Additionally, sensitivity analyses will be performed using the per-protocol database and excluding participants who had injuries or other health problems during the post-assessment evaluations. We will also analyze the effects of attendance and compliance by conducting an analysis including individuals who, in addition to attending \geq 70% of the sessions, also had \geq 70% compliance to the training protocol based on the time within the HIIT heart rate target zones.

535 **2.10 Data management and sharing**

The HEART-BRAIN trial will use two data storage systems: (i) the REDCap platform, an online software for the management of research databases in clinical trials and translational research. RedCap will be used for the storage and management of all non-imaging information, guarantying its trace and safety (34); (ii) the HEART-BRAIN desktop computer will also contain participants' pseudonymized data collected on paper-based forms, that will be scanned and stored, as well as the MRI data. Physical copies of data collection forms and documents will be securely stored in a locked cabinet at the iMUDS facility. Upon enrolment in the trial, participants will be assigned a unique code to be used consistently

543 across all forms and data collection reports, i.e. pseudonymized data, to reduce the risk of exposure 544 resulting from unintended unauthorized access or disclosure. In addition, information linking the 545 pseudonym to the identifiable information must be kept separately and subjected to ensure non-546 attribution to an identified or identifiable individual. The PI will have access to the final dataset and 547 will provide reasonable and responsible access to the pseudonymized data to other researchers. 548 Participants will consent to the use of their pseudonymized data for secondary research, as outlined in 549 the informed consent process. Once a participant is enrolled, all data will undergo thorough quality 550 control checks and be archived following the storage protocol at iMUDS. Quality control measures 551 include visual inspection of imaging data, double correction of paper-pencil cognitive tests, and 552 verification of data validity and integrity in REDCap. The study will adhere to the FAIR principles 553 (Findability, Accessibility, Interoperability, and Reusability), and meta-data will be made publicly 554 available. A DOI (Digital Object Identifier) is issued to every published record. Governance, ethical 555 considerations, and shared trial oversight will be prioritized, aligning with current best practices. Study 556 results, including positive, negative, or inconclusive, will be disseminated through peer-reviewed 557 journals, and national and international conferences, and shared via social media and press releases 558 with participants, caregivers, physicians, and the broader medical and scientific community.

559 The protocol, statistical analyses plan and data management plan will be shared open access. Data files, 560 including pseudonymized individual participant data, will be shared under restricted access and upon 561 reasonable request (contact FBO) due to privacy issues and EU-GDPR regulations. In principle, all 562 collected individual participant data will be available for sharing under the "as open as possible, as 563 closed as necessary" principle. The shared data files will be pseudonymized, and only include 564 participants who provided informed consent for sharing, and sharing is only possible when the data is 565 used for research purposes related to exercise and cardiovascular and brain health. The individual 566 participant data will be available 12 months after the primary outcome paper is published. The specific

567 process of data access will be determined in a later stage. In short, data will be made available upon 568 reasonable requests to the PI (FBO). The data requests must contain the purpose and aim of the 569 research, target variables, and data analysis plan before data sharing. Data will only be shared for 570 research and public health purposes. A data access committee will be created to approve the appropriate 571 data requests. A data monitoring committee does not exist in the funding system in Spain.

572 **3 DISCUSSION**

573 CAD is associated with cognitive and mental health impairment (7-10). However, the mechanisms 574 explaining the connection between the heart and the brain in patients with CAD remain unknown (9). 575 Growing evidence supports the benefits of exercise on the cardiovascular health of individuals with 576 CAD (66-71). Yet, there is scarce knowledge on its influence on brain health. The mechanisms by 577 which different types of exercise might improve brain health or attenuate the cognitive and mental 578 health declines observed in patients with CAD remain to be elucidated. Well-designed intervention 579 studies unraveling the effects and mechanisms by which exercise impacts brain health in patients with 580 CAD will have important clinical and scientific implications. The findings will facilitate moving 581 towards a more 'personalized medicine' approach to exercise prescription in patients with CAD. Thus, 582 the present work provides a comprehensive description of the HEART-BRAIN RCT, following the 583 SPIRIT guidelines for interventional RCTs (30-32). The HEART-BRAIN project aims to examine the 584 effects of two different 12-week supervised exercise interventions (HIIT and HIIT combined with 585 resistance training) compared to usual care on brain and cardiovascular health in patients with CAD. 586 The primary outcome is CBF assessed by a cutting-edge technique called ASL-MRI.

587 Among the few studies that have evaluated the effects of exercise on brain health in individuals with 588 CAD, most of them have focused on health-related quality of life and mental health outcomes (72,

589 73). Other key domains of brain health such as cognition, biological markers of brain health, brain
590 morphology and function, or cerebrovascular outcomes remain unexplored.

591 This study will contribute to the advancement of scientific knowledge in different ways. Firstly, it 592 stands as an innovative intervention of two different exercise programs in accordance with the most 593 updated guidelines (23, 35, 50, 51). By providing a comprehensive description and pre-specified plan 594 of the study protocol, we ensure transparency and enable the scientific community to replicate the 595 protocols and intervention, fostering the dissemination of scientific knowledge. We expect that the 596 intervention and the obtained results will serve as a valuable resource for healthcare and exercise 597 professionals, allowing them to effectively prescribe individualized exercise to patients with CAD. 598 This represents an effective transfer of scientific knowledge to practical settings. This study 599 underscores the importance of systematic and well-defined methodological reports addressing the 600 transparency gaps within the scientific community and facilitating the comprehensive sharing of study 601 information.

602 3.1 Strengths and limitations

603 HEART-BRAIN has several strengths that bolster the reliability and validity of the expected results, 604 such as: i) well-designed RCT framework ensuring random allocation of participants, minimizing 605 selection bias, and enhancing the validity of the causal inferences drawn from the data; ii) extensive 606 brain health mapping, including comprehensive assessments of the different domains of brain health; iii) comprehensive set of variables, including objective, gold-standard test (e.g., CPET) and patient-607 608 reported outcomes (e.g., OoL) to encompass both physical and brain health; iv) continuous heart rate 609 monitoring throughout the exercise sessions allowing for a rigorous compliance analysis, v) time and 610 (estimated) caloric matched exercise groups, ensuring that any observed effects can be attributable to 611 the type of exercise rather than differences in exercise duration or intensity; vi) flexibility is offered to

help participants overcome barriers frequently reported about exercise participation (e.g., trainers adapt to the time that fits best participants' schedule); vii) our mechanistic approach will provide insights on how exercise can impact brain health in patients with CAD and the potential mechanisms explaining the heart-brain connection, such as changes in CBF; and viii) this study holds significant clinical relevance as it specifically targets potential improvements in brain health among patients with CAD, a population known to experience accelerated cognitive decline.

618 The study also has some limitations that must be acknowledged. Since the HEART-BRAIN RCT is 619 implementing HIIT, certain criteria have been established to maximize safety. For example, only 620 individuals with a stable and controlled disease during the outpatient phase will be included. Future 621 trials recruiting a more generalizable group of patients with CAD (i.e., including individuals in a more 622 severe condition) are needed. Further, our study is of relative short duration (12 weeks). While notable 623 physiological changes may manifest within this timeframe, certain significant adaptations may require 624 a longer intervention and follow-up period. Although inherent to exercise-based RCTs, another 625 limitation is the single (and not double) blinding. These limitations should be taken into consideration 626 when interpreting the study's findings.

627 4 Acknowledgments

628 We thank Dr. Veronica Cabanas-Sanchez for performing the randomization of the study.

629 5 Conflict of Interest

630 The authors declare that the research is being conducted in the absence of any commercial or631 financial relationships that could be construed as a potential conflict of interest.

632 6 Author Contributions

Conceptualization and project direction: FBO (principal investigator); Project coordination: AT;
Writing - original draft: AT, FBO; Writing - review & editing: AT, PSU, EAB, IMF, SVA, AC, IEC,
FBO. Formal analysis: EAB, PSU, FBO. All authors contributed intellectually to the design and
development of the methodology and approved the final manuscript of this study protocol. Our
authorship aligns with the ICMJE author contributions criteria (74).

639 7 Funding

640 The HEART-BRAIN Project is supported with the Grant PID2020-120249RB-I00 funded by MCIN/AEI/10.13039/501100011033. Additional support was obtained from the Andalusian 641 642 Government (Junta de Andalucía, Plan Andaluz de Investigación, ref. P20 00124) and the CIBER de 643 Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Granada, Spain. 644 Moreover, EAB has received funding from the European Union's Horizon 2020 research and 645 innovation programme under the Marie Skłodowska-Curie grant agreement No [101064851]. AT has 646 received funding from the Junta de Andalucia, Spain, under the Postdoctoral Research Fellows (Ref. POSTDOC_21_00745). PS-U is supported by a "Margarita Salas" grant from the Spanish Ministry 647 RYC2019-027287-I 648 Universities. IEC supported by grant funded is bv 649 MCIN/AEI/10.13039/501100011033/ and "ESF Investing in your future". IMF is supported by the 650 Spanish Ministry of Science, Innovation and Universities (JDC2022-049642-I). AC was funded by 651 postdoctoral research grants from the Swedish Heart-Lung Foundation (grant number 20230343), the 652 County Council of Ostergotland, Sweden (grant number RÖ-990967), the Swedish Society of 653 Cardiology, and the Swedish Society of Clinical Physiology. BFG is supported by the Spanish Ministry 654 Education. (PID2022-137399OB-I00) funded of Culture and Sport bv 655 MCIN/AEI/10.13039/501100011033 and FSE+. MOR, LSA and JFO are supported by the Spanish Ministry of Science, Innovation and Universities (FPU 22/02476, FPU 21/06192 and FPU 22/03052, 656 657 respectively). JHM is supported by the Spanish Ministry of Science, Innovation and Universities under 658 Beatriz Galindo's 2022 fellowship program (BG22/00075). JSM is supported by the National Agency for Research and Development (ANID)/Scholarship Program/DOCTORADO BECAS CHILE/2022-659 660 (Grant N°72220164). SVA is supported by a Health and Behavior International Collaborative Award 661 by the Society of Behavioral Medicine. This work is part of a PhD thesis conducted in the Doctoral 662 Programme in Biomedicine of the University of Granada, Granada, Spain.

663 The sponsors or funding agencies had no role in the design and conduct of the study, in the collection, 664 analysis, and interpretation of data, in the preparation of the manuscript, or in the review or approval 665 of the manuscript.

667 **REFERENCES**

668 1. Stark B, Johnson C, Roth GA. Global prevalence of coronary artery disease: An update from 669 the global burden of disease study. Journal of the American College of Cardiology.

670 2024;83(13_Supplement):2320-.

671 2. WHO. Cardiovascular diseases (CVDs). World Health Organization; 2021 11 June 2021.

Tsao CW, Aday AW, Almarzooq ZI, Anderson CA, Arora P, Avery CL, et al. Heart disease
and stroke statistics—2023 update: a report from the American Heart Association. Circulation.
2023;147(8):e93-e621.

4. Timmis A, Vardas P, Townsend N, Torbica A, Katus H, De Smedt D, et al. European Society
of Cardiology: cardiovascular disease statistics 2021. J European Heart Journal. 2022;43(8):716-99.

Malakar AK, Choudhury D, Halder B, Paul P, Uddin A, Chakraborty S. A review on
coronary artery disease, its risk factors, and therapeutics. Journal of cellular physiology.
2019;234(10):16812-23.

6. Luengo-Fernandez R, Walli-Attaei M, Gray A, Torbica A, Maggioni AP, Huculeci R, et al.
681 Economic burden of cardiovascular diseases in the European Union: a population-based cost study.
682 Eur Heart J. 2023;44(45):4752-67.

Kaccarino V, Badimon L, Bremner JD, Cenko E, Cubedo J, Dorobantu M, et al. Depression
and coronary heart disease: 2018 position paper of the ESC working group on coronary
pathophysiology and microcirculation. European heart journal. 2020;41(17):1687-96.

8. Tully PJ, Cosh SM, Baumeister H. The anxious heart in whose mind? A systematic review
and meta-regression of factors associated with anxiety disorder diagnosis, treatment and morbidity
risk in coronary heart disease. Journal of psychosomatic research. 2014;77(6):439-48.

689 9. Roger VL. The heart–brain connection: from evidence to action. European heart journal.
690 2017;38(43):3229-31.

691 10. Schievink SH, van Boxtel MP, Deckers K, van Oostenbrugge RJ, Verhey FR, Köhler S.
692 Cognitive changes in prevalent and incident cardiovascular disease: a 12-year follow-up in the
693 Maastricht Aging Study (MAAS). European heart journal. 2022;43(7):e2-e9.

694 11. van Buchem MA, Biessels GJ, Brunner la Rocca HP, de Craen AJ, van der Flier WM, Ikram
695 MA, et al. The heart-brain connection: a multidisciplinary approach targeting a missing link in the
696 pathophysiology of vascular cognitive impairment. Journal of Alzheimer's Disease.
607 2014:42(a4):\$443,\$51

697 2014;42(s4):S443-S51.

698 12. Virani SS, Newby LK, Arnold SV, Bittner V, Brewer LC, Demeter SH, et al. 2023

AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic
 Coronary Disease: A Report of the American Heart Association/American College of Cardiology

701 Joint Committee on Clinical Practice Guidelines. Circulation. 2023;148(9):e9-e119.

13. Dibben GO, Faulkner J, Oldridge N, Rees K, Thompson DR, Zwisler AD, et al. Exercisebased cardiac rehabilitation for coronary heart disease: a meta-analysis. Eur Heart J. 2023;44(6):45269.

Pelliccia A, Sharma S, Gati S, Bäck M, Börjesson M, Caselli S, et al. 2020 ESC Guidelines
on sports cardiology and exercise in patients with cardiovascular disease. Eur Heart J. 2021;42(1):1796.

- Sandercock G, Hurtado V, Cardoso F. Changes in cardiorespiratory fitness in cardiac
 rehabilitation patients: a meta-analysis. International journal of cardiology. 2013;167(3):894-902.
- 710 16. Daulatzai MA. Cerebral hypoperfusion and glucose hypometabolism: Key pathophysiological
 711 modulators promote neurodegeneration, cognitive impairment, and Alzheimer's disease. Journal of
 712 neuroscience research. 2017;95(4):943-72.
- 17. Han H, Zhang R, Liu G, Qiao H, Chen Z, Liu Y, et al. Reduction of cerebral blood flow in
 community-based adults with subclinical cerebrovascular atherosclerosis: A 3.0 T magnetic
 resonance imaging study. Neuroimage. 2019;188:302-8.
- 18. Long JM, Holtzman DM. Alzheimer disease: an update on pathobiology and treatment
 strategies. Cell Metabolism. 2019;179(2):312-39.
- 718 19. Rogers RL, Meyer JS, Mortel KF. After reaching retirement age physical activity sustains
 719 cerebral perfusion and cognition. Journal of the American Geriatrics Society. 1990;38(2):123-8.
- Swain RA, Harris AB, Wiener EC, Dutka MV, Morris HD, Theien BE, et al. Prolonged
 exercise induces angiogenesis and increases cerebral blood volume in primary motor cortex of the
 rat. Neuroscience. 2003;117(4):1037-46.
- Suzuki Y, Helle M, Koken P, Van Cauteren M, van Osch MJ. Simultaneous acquisition of
 perfusion image and dynamic MR angiography using time-encoded pseudo-continuous ASL.
 Magnetic Resonance in Medicine. 2018;79(5):2676-84.
- Taylor RS, Brown A, Ebrahim S, Jolliffe J, Noorani H, Rees K, et al. Exercise-based
 rehabilitation for patients with coronary heart disease: systematic review and meta-analysis of
 randomized controlled trials. The American journal of medicine. 2004;116(10):682-92.
- Bull FC, Al-Ansari SS, Biddle S, Borodulin K, Buman MP, Cardon G, et al. World Health
 Organization 2020 guidelines on physical activity and sedentary behaviour. British journal of sports
 medicine. 2020;54(24):1451-62.
- 732 24. Byrne RA, Rossello X, Coughlan J, Barbato E, Berry C, Chieffo A, et al. 2023 ESC
- Guidelines for the management of acute coronary syndromes: Developed by the task force on the
 management of acute coronary syndromes of the European Society of Cardiology (ESC). J European
 heart journal. 2023;44(38):3720-826.
- Committee PAGA. 2018 physical activity guidelines advisory committee scientific report. US
 Department of Health and Human Services Washington, DC; 2018.
- 738 26. Lang JJ, Prince SA, Merucci K, Cadenas-Sanchez C, Chaput JP, Fraser BJ, et al.
- 739 Cardiorespiratory fitness is a strong and consistent predictor of morbidity and mortality among 740 adults: an overview of meta-analyses representing over 20.9 million observations from 199 unique
- adults: an overview of meta-analyses representing over 20.9 million observations from 199 unique
 cohort studies. British journal of sports medicine. 2024.
- 742 27. Ross R, Blair SN, Arena R, Church TS, Després J-P, Franklin BA, et al. Importance of
 743 assessing cardiorespiratory fitness in clinical practice: a case for fitness as a clinical vital sign: a
 744 scientific statement from the American Heart Association. Circulation. 2016;134(24):e653-e99.
- Maleki S, Hendrikse J, Chye Y, Caeyenberghs K, Coxon JP, Oldham S, et al. Associations of
 cardiorespiratory fitness and exercise with brain white matter in healthy adults: A systematic review
 and meta-analysis. Brain imaging and behavior. 2022;16(5):2402-25.
- Smith EC, Pizzey FK, Askew CD, Mielke GI, Ainslie PN, Coombes JS, et al. Effects of
 cardiorespiratory fitness and exercise training on cerebrovascular blood flow and reactivity: a

- systematic review with meta-analyses. American journal of physiology Heart and circulatoryphysiology. 2021;321(1):H59-h76.
- 752 30. Chan AW, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K, et al. SPIRIT
 753 2013 statement: defining standard protocol items for clinical trials. Ann Intern Med.
 754 2012 159(2) 200 7

754 2013;158(3):200-7.

Chan AW, Tetzlaff JM, Gøtzsche PC, Altman DG, Mann H, Berlin JA, et al. SPIRIT 2013
explanation and elaboration: guidance for protocols of clinical trials. Bmj. 2013;346:e7586.

Butcher NJ, Monsour A, Mew EJ, Chan A-W, Moher D, Mayo-Wilson E, et al. Guidelines
for reporting outcomes in trial protocols: the SPIRIT-outcomes 2022 extension. JAMA cardiology.
2022;328(23):2345-56.

- Schulz KF, Altman DG, Moher D. CONSORT 2010 Statement: updated guidelines for
 reporting parallel group randomised trials. BMC medicine. 2010;8:18.
- 762 34. Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O'Neal L, et al. The REDCap
- consortium: building an international community of software platform partners. Journal ofbiomedical informatics. 2019;95:103208.
- Taylor JL, Holland DJ, Spathis JG, Beetham KS, Wisløff U, Keating SE, et al. Guidelines for
 the delivery and monitoring of high intensity interval training in clinical populations. Progress in
 cardiovascular diseases. 2019;62(2):140-6.
- 36. Morishita S, Tsubaki A, Nakamura M, Nashimoto S, Fu JB, Onishi H. Rating of perceived
 exertion on resistance training in elderly subjects. Expert review of cardiovascular therapy.
 2019;17(2):135-42.
- 37. Rognmo Ø, Moholdt T, Bakken H, Hole T, Mølstad P, Myhr NE, et al. Cardiovascular risk of
 high-versus moderate-intensity aerobic exercise in coronary heart disease patients. Circulation.
 2012;126(12):1436-40.
- 38. Wewege MA, Ahn D, Yu J, Liou K, Keech A. High-intensity interval training for patients
 with cardiovascular disease—is it safe? A systematic review. Journal of the American Heart
 Association. 2018;7(21):e009305.
- Taylor JL, Holland DJ, Keating SE, Leveritt MD, Gomersall SR, Rowlands AV, et al. Shortterm and Long-term Feasibility, Safety, and Efficacy of High-Intensity Interval Training in Cardiac
 Rehabilitation: The FITR Heart Study Randomized Clinical Trial. JAMA Cardiol. 2020;5(12):13829.
- 781 40. Gallagher RM, Kirkham JJ, Mason JR, Bird KA, Williamson PR, Nunn AJ, et al.
- Development and inter-rater reliability of the Liverpool adverse drug reaction causality assessment
 tool. PloS one. 2011;6(12):e28096.
- 41. Shah S. Common terminology criteria for adverse events. National Cancer Institute: USA.2022.
- Kilroy E, Apostolova L, Liu C, Yan L, Ringman J, Wang DJ. Reliability of two-dimensional
 and three-dimensional pseudo-continuous arterial spin labeling perfusion MRI in elderly populations:
 comparison with 15O-water positron emission tomography. Journal of magnetic resonance imaging :
 JMRI. 2014;39(4):931-9.
- Wang DJ, Alger JR, Qiao JX, Gunther M, Pope WB, Saver JL, et al. Multi-delay multi parametric arterial spin-labeled perfusion MRI in acute ischemic stroke Comparison with dynamic
 wassertibility contrast enhanced perfusion imaging. Neurophysical 2012;2:1-7
- susceptibility contrast enhanced perfusion imaging. NeuroImage Clinical. 2013;3:1-7.

44. Ojeda N, del Pino R, Ibarretxe-Bilbao N, Schretlen D, Peña J. Test de evaluación cognitiva de
Montreal: normalización y estandarización de la prueba en población española. Revista de
neurología. 2016;63(11):488-96 % @ 0210-010.

Reitan RM. Validity of the Trail Making Test as an indicator of organic brain damage.
Perceptual and motor skills. 1958;8(3):271-6 % @ 0031-5125.

798 46. Wechsler D. WAIS-IV: Escala Wechsler de inteligencia para adultos-IV. 2008.

- 47. Zelazo PD, Anderson JE, Richler J, Wallner-Allen K, Beaumont JL, Weintraub S. II. NIH
- Toolbox Cognition Battery (CB): measuring executive function and attention. Monogr Soc Res Child
 Dev. 2013;78(4):16-33.

48. Erickson KI, Voss MW, Prakash RS, Basak C, Szabo A, Chaddock L, et al. Exercise training
increases size of hippocampus and improves memory. Proc Natl Acad Sci U S A. 2011;108(7):301722.

805 49. Solis-Urra P, Molina-Hidalgo C, García-Rivero Y, Costa-Rodriguez C, Mora-Gonzalez J,

Fernandez-Gamez B, et al. Active Gains in brain Using Exercise During Aging (AGUEDA): protocol
for a randomized controlled trial. Front Hum Neurosci. 2023;17:1168549.

808 50. Bayles MP. ACSM's exercise testing and prescription: Lippincott williams & wilkins; 2023.

809 51. Mezzani A, Hamm LF, Jones AM, McBride PE, Moholdt T, Stone JA, et al. Aerobic exercise

810 intensity assessment and prescription in cardiac rehabilitation: a joint position statement of the

811 European Association for Cardiovascular Prevention and Rehabilitation, the American Association of

812 Cardiovascular and Pulmonary Rehabilitation, and the Canadian Association of Cardiac

813 Rehabilitation. Journal of cardiopulmonary rehabilitation and prevention. 2012;32(6):327-50.

52. Shao X, Ma SJ, Casey M, D'Orazio L, Ringman JM, Wang DJJ. Mapping water exchange
across the blood-brain barrier using 3D diffusion-prepared arterial spin labeled perfusion MRI. Magn
Reson Med. 2019;81(5):3065-79.

817 53. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018

818 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021819 104.

- 54. Langhammer B, Stanghelle JK. The Senior Fitness Test. Journal of physiotherapy.
 2015;61(3):163.
- Merellano-Navarro E, Collado-Mateo D, García-Rubio J, Gusi N, Olivares PR. Validity of
 the International Fitness Scale "IFIS" in older adults. Experimental gerontology. 2017;95:77-81.

56. Izal M, Montorio I. Adaptation of the Geriatric Depression Scale in Spain: A preliminary
study. Clinical Gerontologist. 1993;13(2):83-91.

- 57. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta psychiatrica
 Scandinavica. 1983;67(6):361-70.
- 828 58. Remor E. Psychometric Properties of a European Spanish Version of the Perceived Stress
 829 Scale (PSS). The Spanish Journal of Psychology. 2006;9(1):86-93.
- 830 59. Russell D, Peplau LA, Cutrona CE. The revised UCLA Loneliness Scale: concurrent and
 831 discriminant validity evidence. Journal of personality and social psychology. 1980;39(3):472-80.
- 832 60. Robins R. Measuring global self-esteem: Construct validation of a single-item measure and
 833 the Rosenberg self-esteem scale. Personality Social Psychology Bulletin. 2001;27:151-61.

- 61. Cutrona CE, Russell DW. The provisions of social relationships and adaptation to stress.
 Advances in personal relationships. 1987;1(1):37-67.
- Alonso J, Prieto L, Antó J. The Spanish version of the SF-36 Health Survey (the SF-36 health
 questionnaire): an instrument for measuring clinical results. Medicina clínica. 1995;104(20):771-6.

Migueles JH, Rowlands AV, Huber F, Sabia S, van Hees VT. GGIR: a research community–
driven open source R package for generating physical activity and sleep outcomes from multi-day
raw accelerometer data. Journal for the Measurement of Physical Behaviour. 2019;2(3):188-96.

64. Troiano RP, Stamatakis E, Bull FC. How can global physical activity surveillance adapt to
evolving physical activity guidelines? Needs, challenges and future directions. British journal of
sports medicine. 2020;54(24):1468-73.

- Li G, Taljaard M, Van den Heuvel ER, Levine MA, Cook DJ, Wells GA, et al. An
 introduction to multiplicity issues in clinical trials: the what, why, when and how. International
 journal of epidemiology. 2017;46(2):746-55.
- 847 66. Anderson L, Oldridge N, Thompson DR, Zwisler A-D, Rees K, Martin N, et al. Exercise-
- Based Cardiac Rehabilitation for Coronary Heart Disease: Cochrane Systematic Review and MetaAnalysis. Journal of the American College of Cardiology. 2016;67(1):1-12.

67. Goldhammer E, Tanchilevitch A, Maor I, Beniamini Y, Rosenschein U, Sagiv M. Exercise
training modulates cytokines activity in coronary heart disease patients. International Journal of
Cardiology. 2005;100(1):93-9.

- 853 68. Niessner A, Richter B, Penka M, Steiner S, Strasser B, Ziegler S, et al. Endurance training
 854 reduces circulating inflammatory markers in persons at risk of coronary events: impact on plaque
 855 stabilization? Atherosclerosis. 2006;186(1):160-5.
- 856 69. Lavie CJ, Milani RV. Cardiac Rehabilitation and Exercise Training in Secondary Coronary
 857 Heart Disease Prevention. Progress in Cardiovascular Diseases. 2011;53(6):397-403.
- 858 70. Pareja-Galeano H, Garatachea N, Lucia A. Exercise as a polypill for chronic diseases.
 859 Progress in Molecular Biology & Translational Science
- 860 2015;135:497-526.

71. Muscella A, Stefàno E, Marsigliante S. The effects of exercise training on lipid metabolism
and coronary heart disease. American journal of physiology Heart and circulatory physiology.
2020;319(1):H76-h88.

- Gomes-Neto M, Duraes AR, Reis HFCd, Neves VR, Martinez BP, Carvalho VO. Highintensity interval training versus moderate-intensity continuous training on exercise capacity and
 quality of life in patients with coronary artery disease: A systematic review and meta-analysis. J
 European Journal of Preventive Cardiology. 2017;24(16):1696-707.
- Yu H, Zhao X, Wu X, Yang J, Wang J, Hou L. High-intensity interval training versus
 moderate-intensity continuous training on patient quality of life in cardiovascular disease: a
 systematic review and meta-analysis. Scientific Reports. 2023;13(1):13915.
- 871 74. Editors ICoMJ. Defining the role of authors and contributors. 2018.
- 872 75. Muñoz-García M, Cervantes S, Razquin C, Guillén-Grima F, Toledo JB, Martínez-González

873 M, et al. Validation study of a Spanish version of the modified Telephone Interview for Cognitive

874 Status (STICS-m). Gaceta sanitaria. 2019;33(5):415-20.

- 875 76. Brandt J, Spencer M, Folstein M. The Telephone Interview for Cognitive Status.
- 876 Neuropsychiatry, Neuropsychology, & Behavioral Neurology. 1988;1(2):111-7.

FIGURES AND TABLES



Figure 1. Visual representation of the study design in the HEART-BRAIN trial. ACC: Accelerometry; CAD: coronary artery disease; CPET: cardiopulmonary exercise test; ECO: echography; COG; cognitive function tests; MRI: magnetic resonance imaging UC: usual care. *Post-intervention assessment includes similar outcomes compared to baseline assessment.

Table 1. HEART-BRAIN inclusion and exclusion criteria for selecting participants.

INCLUSION CRITERIA:

1. Men and women aged 50 - 75 years old, both inclusive (*Contingency plan: increase the range to 40-75 if we have difficulties to get the study sample)

2. Must have stable coronary artery disease (phase III), proven by invasive coronary angiography or CT with at least one coronary stenosis with > 50% luminal reduction.

3. Able to speak and read fluent Spanish.

4. Living in Granada city or surrounding areas (able to come to evaluations and exercise program)

5. Living in the community during the study (i.e. independent home, non-assisted living facilities)

6. Left ventricular ejection fraction \geq 45%, determined by echocardiography

7. Functional grade I-II according to the New York Heart Association (NYHA) scale.

8. Sinus rhythm.

9. Stable optimal medical treatment (determined by a cardiologist).

10. Physically inactive, considering: 1) not meeting the WHO recommendations in neither the aerobic nor strength part, and 2) not participating in a planned and structured exercise program at least 3 days per week for the last 3 months. Both conditions must be met to be included and will be ascertained during a screening phone call. Note: going for a walk will not be considered an exclusion reason.

11. No signs of manifest cognitive disorder according to the Spanish Telephone Interview for Cognitive Status-modified (STICS-m) scoring of 26 and above (75, 76).

EXCLUSION CRITERIA:

1. Use of assisted walking devices.

2. Acute coronary syndrome in the last year.

3. Coronary artery by-pass surgery or percutaneous intervention in the last 6 months.

4. Treatment for any type of cancer in the last 2 years.

5. Hospitalization in the intensive care unit in the last 6 months.

6. Current psychiatric diagnosis (visit to psychiatrist and drug treatment prescription in the last year), including major depression and history of psychiatric illness (schizophrenia, bipolar disorder, hallucinations).

7. Grade III obesity (BMI > 40).

8. Diagnosis of neurological or cerebrovascular disorder (e.g., stroke).

9. Medical contraindication for inclusion in an exercise program.

10. Diabetes with uncontrolled hyperglycemia.

11. Resting blood pressure > 180/110 mmHg.

12. Exercise-induced chest pain or changes in the ST segment suggestive of severe ischemia during exercise testing

13. Severe inducible ischemia

14. Low functional capacity in ergometry (<5 METS).

15. Obstructive left main artery disease (significant disease > 50% obstruction)

16. Unstable angina

17. Uncontrolled cardiac arrhythmia

18. Presence of metal implants (e.g., pacemaker or implantable cardioverter-defibrillator-ICD) not compatible with MRI (reported during the phone screening)

medRxiv preprint doi: https://doi.org/10.1101/2024.05.22.24307744; this version posted May 22, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license . 19. Paroxysmal or persistent atrial fibrillation with episodes in the last 6 months.

- 20. Moderate to severe pulmonary hypertension.
- 21. Acute endocarditis, myocarditis, or pericarditis.
- 22. Moderate to severe heart valve disease (grade 3-4)
- 23. Acute pulmonary embolism, or deep vein thrombosis.
- 24. Aortic dissection

25. High-grade heart block or complete left bundle branch block or altered basal electrocardiogram with difficulties to interpret in exercise testing.

- 26. Hypertrophic obstructive cardiomyopathy.
- 27. Retinopathy.
- 28. Severe autonomic or peripheral neuropathy.
- 29. Acute systemic illness or fever.
- 30. Acute or chronic renal failure (estimated glomerular filtration rate < 30 mL/min)

31. Pulmonary fibrosis or interstitial disease (respiratory failure or severe COPD confirmed by pneumological study).

- 32. Recent treatment for alcohol or substance abuse.
- 33. Claustrophobia.
- 34. Any surgery or medical intervention planned during the study period.
- 35. Plans to participate or current participation in other studies that might interfere with this study.
- 36. Current pregnancy or intention to get pregnant during the study period.

CT: computer tomography; METS: metabolic equivalent; COPD: Chronic obstructive pulmonary disease

Outcomes	Instrument / Tool			Post		
	PRIMARY OUTCOME					
Cerebral blood flow	MRI: turbo gradient spin echo-pseudo continuous arterial spin labeling	х		х		
	SECONDARY OUTCOMES					
Cerebral vascularization	MRA: Time-of-flight angiography	х		x		
Executive function	Desing Substitution Symbol Test; Trail Making Test; Spatial Working Memory Test (E-prime); Dimensional Card Sort Test; Flanker Test; Picture Sequence Test; and List Sort Working Memory Test	X		X		
General cognition	Montreal Cognitive Assessment test (MOCA)	х		х		
Cardiorespiratory fitness	Treadmill Cardiorespiratory exercise test with gas exchange analysis	Х		х		
	OTHER OUTCOMES					
Brain structure and func	tion					
Blood brain barrier	MRI: 3D diffusion-prepared arterial spin labelled perfusion	х		x		
Brain morphology	MRI: T1-weighted MPRAGE structural	х		х		
White matter structure	MRI: Diffusion weighted acquisition	х		х		
Brain function	Functional MRI: Resting state echo planar imaging	х		x		
Biological samples						
Neurology biomarkers						
Inflammatory biomarkers	Blood and saliva samples (type of analysis to be determinate with the best method available at moment of analysis)	X		x		
Cardiovascular biomarkers	Blood samples (type of analysis to be determinate with the best method available at moment of analysis)	х		x		
Gene expression and epigenetics	Genetic analysis in blood and saliva samples (qRT-PCR and others to be determinate with the best method available at moment of analysis)	x		x		
Oral and gut microbiota	Saliva and fecal samples	х		х		
Hemodynamics						
Vascular hemodynamics	Carotid ultrasound	х		х		
Cardiac hemodynamics	Echocardiography	х		х		
Transcranial hemodynamics	Transcranial ultrasound	х		х		
Blood pressure	Blood pressure monitor	х		х		
Arterial stiffness	Carotid-femoral pulse wave velocity, SphygmoCor XCEL	х		х		
Physical functioning and body composition						
Muscle strength	Chair stand test, arm curl test and hand dynamometer TKK 5101	х		х		
Physical function	Senior Fitness Test and 6-min walking test	х		х		
Body composition	Dual-energy x-ray absorptiometer (DXA) and a TANITA's Bioelectrical Impedance Analysis	Х		х		
Mental health and behaviour						
Depression	Hospital Anxiety and Depression Scale	Х		х		
Anxiety	Hospital Anxiety and Depression Scale	Х		х		
Stress	Perceived Stress Scale	Х		х		
Loneliness	UCLA Loneliness Scale	х		х		

medRxiv preprint doi: https://doi.org/10.1101/2024.05.22.24307744; this version posted May 22, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.					
Self-esteem	It is made available under a CC-BY 4.0 International license . Rosenberg Self-Esteem Scale	х	х		
Social support	Social Provisions Scale	х	Х		
Health-related quality of life	Health Survey Short Form (SF-36)	х	Х		
Physical activity	Accelerometer Axivity AX (pre and mid), and a self-reported questionnaire based on the Global Physical Activity Questionnaire	x	Х		
Sedentary behavior	Accelerometer Axivity AX (pre and mid), and a self-reported questionnaire based on the Global Physical Activity Questionnaire	х	Х		
Sleep duration and quality	Accelerometer Axivity AX (pre and mid) and a self-reported questionnaire	х	Х		
Diet behavior	14-item Questionnaire of Mediterranean Diet Adherence, and self- reported question for supplements	х	X X		
DESCRIPTIVES OR COVARIATES FOR ANALYSES					
Educational level					

Ethnicity Smoking habits Alcohol consumption Medication

Comorbidities (e.g., dyslipidemia, hypertension, type 2 diabetes)

Family history of dementia

Handedness

COVID-19 history

Genotyping of APOE, BDNF and others

Pre: baseline assessments; mid: assessments at 6 weeks; post: assessments at 12 weeks, just after finish intervention MRI: magnetic resonance imaging; qRT-PCR: quantitative real-time polymerase chain reaction; APOE: Apolipoprotein E; BDNF: Brain-Derived Neurotrophic Factor.

medRxiv preprint doi: https://doi.org/10.1101/2024.05.22.24307744; this version posted May 22, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC_BY 4.0 International license. Table 3. Brain Magnetic Resonance Imaging (MRI) parameters of the HEART-BRAIN trial

SEQUENCE	PARAMETERS	OUTCOMES	ACQUISITION TIME (MIN)
TOF (Time of flight angiography)	TR=21 ms, TE=3.43 ms, Flip angle: 18grad., FOV=200 mm, acquisition bandwidth of 155 Hz/PX, 44 slices (18.2% oversampling), resolution = $0.3 \times 0.3 \times 0.8$ mm3	Angiography (cerebral vascularization)	8
T1-weighted MPRAGE structural	Sagittal, 0.8 mm isotropic resolution, TE/TI/TR = 2.31/1060/2400 ms, FOV = 256 mm, 224 slices	Brain structure	6
diffusion- prepared pCASL (DP- pCASL) sequence	TR = 4 sec, TE = 36.5 ms, FOV = 224 mm, matrix size = 64×64 , 12 slices (10% oversampling), resolution = $3.5 \times 3.5 \times 8$ mm3, label/control duration = 1500 ms, centric ordering, and optimized timing of background suppression for gray matter (GM) and white matter (WM)	Blood brain barrier permeability	10
Resting state EPI	Resolution: $2.5 \times 2.5 \times 2.5$ mm, TE/TR = 40/1000 ms, Multiband factor = 8 (CMRR EPI sequence), 64 slices, 480 measurements	Resting BOLD (Blood Oxygen Level Dependent)	5
Diffusion weighted acquisition	Resolution: $2 \times 2 \times 2$ mm, TE/TR = 95.6/2800 ms, Multiband factor = 4, b-values of 1500, 3000 s/mm2, 64 gradient directions	White matter microstructure	8
pCASL TGSE	3D GRASE pCASL sequence, Resolution: $3.1 \times 3.1 \times 2.5$ mm, TE/TR = 23.64/4300 ms, 48 slices, Multiple Post-labeling delay [0.5, 0.5, 1, 1, 1.5, 1.5, 2.0, 2.0, 2.0 s], Background Suppression, 9 measurements for labeling and control, 4 segment readout	Cerebral blood flow	6
MRI- Abdominal	Resolution: $2 \times 2 \times 2$ mm, TE1-2/TR = 1.23-2.46/5.21 ms, flip angle 9°, CAIPIRINHA iPAT factor = 4, FOV = 448 mm	Visceral adipose tissue	5

FOV: Field of View; Hz: hertz; PX: pixel; MPRAGE: Magnetization Prepared Rapid Gradient Echo; pCASL: pseudo-Continuous Arterial Spin Labelling; TE: Echo Time; TI: Inversion Time; TR: Repetition Time; EPI: Echo Planar Imaging; TGSE: Turbo Gradient Spin-Echo

Cognitive test	Day / session	Format	Domain	Time
Spanish Telephone Interview for Cognitive Status (75, 76)	Telephone screening	Verbal	General cognition	10 min
Montreal Cognitive Assessment (44)	2	Verbal-paper- pencil	General cognition	10 min
Trail Making Test A and B (45)	2	Paper-pencil	Executive function: Cognitive flexibility	5 min
Digit Symbol Substitution Test (46)	2	Paper-pencil	Processing speed and attention	5 min
Dimensional Change Card Sort Test (47)	1	Computerized	Executive function: Cognitive flexibility and inhibition	5 min
List Sorting Working Memory Test (47)	1	Computerized	Executive function: Working memory (verbal)	5 min
Flanker Test (47)	1	Computerized	Executive function: inhibitory control and attention	5 min
Spatial Working Memory Test (48)	3	Computerized	Executive function: Working memory (spatial)	10 min
Picture Sequence Memory Test (47)	1	Computerized	Episodic memory	5 min

SAMPLE	ANALYSIS TARGET	PRELIMINARY ANALYSIS PLAN
Blood samples		
Plasma	Aβ (Amyloid beta) peptides Aβ1-42, Aβ1-40; BD-tau and P-tau; Neurofilament light chain (NFL); Glial fibrillary acidic protein (GFAP); Vascular endothelial growth factor (VEGF); chemokine C-X-C motif ligand 13 (CXCL-13); IgM-1; IL-17; pancreatic polypeptide (PPY); Adiponectin; Brain- derived neurotrophic factor (BDNF); Cathepsin B; vascular cell adhesion molecule 1 (VACM-1); C-reactive protein (CRP); high-sensitivity CRP; Interleukin-6 (IL-6); Interleukin-17 (IL- 17); Tumor necrosis factor (TNF-Alpha); Klotho; GLP-1, Clusterin	Plasma biomarker Ab (Amyloid beta) peptides Ab1-42, Ab1-40; BD-tau and P-tau; Neurofilament light chain - NFL GFAP- concentrations will be measured using Single molecule array (Simoa) methods on an HD-X instrument and commercial assays from Quanterix. Key inflammatory biomarkers will be analyzed with automated blood cell counters and quantified by multiple analyte profiling technology (MILLIPLEX R MAP Human High Sensitivity T-Cell Magnetic Bead Panel, EMD Millipore Corporation, Missouri, U.S.A.) Klotho will be determined using a solid-phase sandwich enzyme-linked immunosorbent assay (Demeditec, Kiel, Germany) according to the manufacturer's protocol.
Peripheral Blood Mononuclear Cells	Telomere length	A commercial DNA isolation kit (Qiagen, Barcelona, Spain) will be used to extract genomic DNA from isolated PBMCs. Relative telomere length will be determined by quantitative real-time polymerase chain reaction (qRT-PCR) using the telomere/single-copy gene ratio (T/S)
Serum	Insulin-like growth factor 1 (IGF-1); Insulin; Glucose; Glycated Hemoglobin (HbA1c), creatinine, Serum fatty acid (SFA-1), total, HDL and LDL cholesterol, glomerular filtration rate, triglycerides	IGF-1, insulin, glucose, glycated hemoglobin (HbA1c) and serum fatty acids (SFA-1) will be analyzed using XMap technology (Luminex Corporation, Austin, TX) and human monoclonal antibodies (Milliplex Map Kit; Millipore, Billerica, MA). Total cholesterol, HDL-C, LDL-C, triglycerides, and glucose will be assessed using a spectrophotometer. Insulin will be assessed by chemiluminescence immunoassay.
Whole Blood	Glycated hemoglobin (A1c), RNA and DNA analyses	Blood specimens will be used for genotyping. The genotypes will be determined using TaqMan genotyping assays (e.g., APOE). A commercial RNA isolation kit (Qiagen, Barcelona, Spain) will be used to extract total RNA from whole blood samples. The selection of specific miRNAs will be based on the existing bibliographic information. In accordance with this, the selected miRNA will be evaluated using Taqman probes.
Saliva samples	Oral microbiota and other potential biomarkers	To be determined with the best method available at the moment of analysis
Fecal samples	Metagenomic Analysis of the Gut Microbiome	To be determined with the best method available at the moment of analysis